"Take with or without food, however avoid lipid-rich meals."@en . . . . . . . . . . . "Avoid alcohol, especially with the oral solution since it contains propylene glycol which competes with alcohol for alcohol dehydrogenase metabolism."@en . "approved"@en . "Ampr\u00E9navir"@en . "Amprenavir"@en . . "Rapidly absorbed after oral administration in HIV-1-infected patients with a time to peak concentration (T_max) typically between 1 and 2 hours after a single oral dose. The absolute oral bioavailability of amprenavir in humans has not been established. "@en . . . . . . . . . . " "@en . . . "\"DrugSyn.org\":http://www.drugsyn.org/Amprenavir.htm"@en . . . . . . "Human Immunodeficiency Virus"@en . . . "Amprenavir is a protease inhibitor used to treat HIV infection."@en . . "7.1-10.6 hours"@en . "Amprenavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles."@en . . . . "Amprenavirum"@en . . . . . . . . . "Amprenavir"@en . . "161814-49-9"@en . . . . "Vitamin E increases amprenavir bioavailability."@en . "Agenerase"@en . . . . "(3S)-Tetrahydro-3-furanyl ((1S,2R)-3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)carbamate"@en . . "Very high (90%). Amprenavir has the highest affinity for alpha(1)-acid glycoprotein."@en . . . "For the treatment of HIV-1 infection in combination with other antiretroviral agents."@en .